



04-1305
1616
Express Mail No.: EV452775033US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Christine Dingivan

Confirmation No. 7146

Application No.: 10/091,313

Group Art Unit: 1616

Filed: March 4, 2002

Examiner: Not Yet Assigned

For: METHODS OF PREVENTING OR TREATING
INFLAMMATORY OR AUTOIMMUNE
DISORDERS BY ADMINISTERING CD2
ANTAGONISTS IN COMBINATION WITH OTHER
PROPHYLACTIC OR THERAPEUTIC AGENTS

Attorney Docket No.: 10271-063-999

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES TRANSMITTAL OF SEQUENCE LISTING**

Commissioner For Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In response to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed March 9, 2005, in connection with the captioned application, Applicant submits herewith a Substitute Sequence Listing in written form and in computer readable form pursuant to 37 C.F.R. § 1.821(c) and (e). Pursuant to 37 C.F.R. § 1.6, the filing of this transmittal is timely filed on the next succeeding business day, since April 9, 2005 falls on a Saturday.

In accordance with 37 C.F.R. § 1.821(f), the undersigned hereby states that the content of the Substitute Sequence Listing information recorded in computer readable form is identical to the written sequence listing. In accordance with 37 C.F.R. § 1.821(g), the undersigned further states that the written and the computer readable forms of the Sequence Listing do not include new matter.

Accordingly, Applicant respectfully requests that the Substitute Sequence Listing replace the Sequence Listing originally filed and be entered into the present application file.

Respectfully submitted,

Date: April 11, 2005

By: M. B. Brivanlou 40,922
Margaret B. Brivanlou (Reg. No.)
JONES DAY
222 East 41st Street
New York, New York 10017
(212) 326-3939

Enclosures




UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/091,313	03/04/2002	Christine Dingivan	10271-063

20583
 JONES DAY
 222 EAST 41ST ST
 NEW YORK, NY 10017



CONFIRMATION NO. 7146

FORMALITIES LETTER



OC000000015398853

Date Mailed: 03/09/2005

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Filing Date Granted

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR §§ 1.821-1.825. The application must be in sequence compliance before examination on the merits.

APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 CFR § 1.821(g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR § 1.136. In no case may an applicant extend the period for response beyond the six-month statutory period. Direct the response to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450.

See the attachment.

Applicant Must Provide as part of the response:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

To Download Patent Software, visit <http://www.uspto.gov/web/patents/software.htm>

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patent Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patent Software Program Help @ ebc@uspto.gov

Commissioner for Patents
P.O. Box 1450
Alexandria VA 22313-1450

A copy of this notice MUST be returned with the reply.



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE